Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

医学 内科学 危险系数 化疗 养生 比例危险模型 肿瘤科 妇科肿瘤学 卵巢癌 浆液性液体 胃肠病学 优势比 癌症 外科 置信区间
作者
Devansu Tewari,James Java,Ritu Salani,Deborah K. Armstrong,Maurie Markman,Thomas J. Herzog,Bradley J. Monk,John K. Chan
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:33 (13): 1460-1466 被引量:264
标识
DOI:10.1200/jco.2014.55.9898
摘要

Purpose To determine long-term survival and associated prognostic factors after intraperitoneal (IP) chemotherapy in patients with advanced ovarian cancer. Patients and Methods Data from Gynecologic Oncology Group protocols 114 and 172 were retrospectively analyzed. Cox proportional hazards regression models were used for statistical analyses. Results In 876 patients, median follow-up was 10.7 years. Median survival with IP therapy was 61.8 months (95% CI, 55.5 to 69.5), compared with 51.4 months (95% CI, 46.0 to 58.2) for intravenous therapy. IP therapy was associated with a 23% decreased risk of death (adjusted hazard ratio [AHR], 0.77; 95% CI, 0.65 to 0.90; P = .002). IP therapy improved survival of those with gross residual (≤ 1 cm) disease (AHR, 0.75; 95% CI, 0.62 to 0.92; P = .006). Risk of death decreased by 12% for each cycle of IP chemotherapy completed (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Factors associated with poorer survival included: clear/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.83 to 4.24; P < .001), gross residual versus no visible disease (AHR, 1.89; 95% CI, 1.48 to 2.43; P < .001), and fewer versus more cycles of IP chemotherapy (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Younger patients were more likely to complete the IP regimen, with a 5% decrease in probability of completion with each year of age (odds ratio, 0.95; 95% CI, 0.93 to 0.96; P < .001). Conclusion The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
H与K完成签到,获得积分10
刚刚
风趣青槐完成签到,获得积分10
刚刚
planA完成签到,获得积分10
1秒前
LiBertY发布了新的文献求助10
2秒前
情怀应助ii采纳,获得30
2秒前
4秒前
4秒前
bkagyin应助鱼儿想游采纳,获得10
5秒前
睡觉睡觉完成签到,获得积分10
6秒前
脑洞疼应助知性的冰棍采纳,获得30
8秒前
fhhkckk3发布了新的文献求助10
9秒前
23lk发布了新的文献求助10
10秒前
Kim关注了科研通微信公众号
10秒前
健忘的无招完成签到,获得积分10
18秒前
聪明凌柏完成签到 ,获得积分10
19秒前
19秒前
23秒前
马大勺发布了新的文献求助10
25秒前
慕青应助23lk采纳,获得10
28秒前
28秒前
29秒前
29秒前
31秒前
我到了啊发布了新的文献求助10
32秒前
斯文败类应助Connor采纳,获得10
33秒前
生动路人应助Dank1ng采纳,获得10
33秒前
tracey发布了新的文献求助10
35秒前
choiyxh发布了新的文献求助50
35秒前
shinble完成签到,获得积分10
35秒前
汉堡包应助123123采纳,获得10
36秒前
hugeng完成签到,获得积分10
39秒前
无花果应助从容幼南采纳,获得10
39秒前
徐家欢完成签到 ,获得积分10
40秒前
shinble发布了新的文献求助10
43秒前
高文强发布了新的文献求助10
47秒前
子唯完成签到,获得积分10
48秒前
TTSDW完成签到,获得积分10
49秒前
李健应助1111采纳,获得10
51秒前
52秒前
56秒前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
Problems of point-blast theory 400
北师大毕业论文 基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 390
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
Novel Preparation of Chitin Nanocrystals by H2SO4 and H3PO4 Hydrolysis Followed by High-Pressure Water Jet Treatments 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3999264
求助须知:如何正确求助?哪些是违规求助? 3538622
关于积分的说明 11274738
捐赠科研通 3277531
什么是DOI,文献DOI怎么找? 1807597
邀请新用户注册赠送积分活动 883950
科研通“疑难数据库(出版商)”最低求助积分说明 810080